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ABSTRACT
Introduction: Pericardial effusion (PE) is a postoperative complication of cardiac 
valve surgery, related to early hospital readmissions and death. We aimed to 
describe its incidence and to identify predictive factors of moderate-to-severe PE in 
a contemporary cohort.
Methods: We retrospectively reviewed medical records of all consecutive patients 
submitted to cardiac valve surgery in a tertiary teaching hospital from January 2012 to 
July 2014, where echocardiography was routinely performed before patient discharge. 
Moderate-to-severe PE was defined as ≥ 10 mm of thickness, or signs of cardiac 
tamponade on echocardiography. Additional clinical and perioperative data were 
extracted from medical records using a standardized protocol.
Results: Of 353 patients, 335 underwent a predischarge echocardiography. From 
these, 27 patients (8%; mean age: 62 years; standard deviation 12 years; 70% male) 
had moderate-to-severe PE. These patients had a higher prevalence of previous stroke 
(22% vs. 8%; p = 0.009) and oral anticoagulation (international normalized ratio > 2) 
prior to the surgery (11 vs. 2%; P = 0.002). In patients with moderate-to-severe PE, 
surgeries had longer ischemia (p < 0.001) and cardiopulmonary bypass (p < 0.001) 
times, and the prevalence of postoperative atrial fibrillation was higher (56% vs. 32%; 
p = 0.011) than in patients with absent or small PE. Hospital mortality was also higher 
(15% vs. 3%; p = 0.002) in patients with moderate-to-severe PE.
Conclusions: Eight percent of patients submitted to cardiac valve surgery developed 
moderate-to-severe PE. Moreover, PE was associated with pre- and post-surgery 
conditions likely related to the coagulation state, though a cause-effect relationship 
could not be inferred. Noteworthy, this condition was associated with higher in-hospital 
morbidity and mortality.
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Pericardial effusion (PE) is a postoperative complication of open-heart surgery. 
It may lead to cardiac tamponade, early readmissions and reinterventions, and 
increased mortality rates1. The reported incidence of postoperative PE varies 
from 1% to 77%2,3 depending on the type of surgery, clinical characteristics, 
and the criteria used for identification and quantification. Cardiac valve surgery 
is one of the procedures most related to the development of PE3. A higher 
risk for postoperative PE has been associated with higher body surface area, 
pulmonary thromboembolism, hypertension, renal failure, immunosuppression, 
emergency surgery status, type of cardiac operation other than coronary artery 
bypass grafting, and prolonged cardiopulmonary bypass4,5. As a consequence, 
identifying predictors for the development of PE after cardiac valve surgery 
may help to prevent or reduce its occurrence.
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In this study, we aimed to determine the incidence 
of moderate-to-severe PE after cardiac valve surgery 
and the risk factors associated with this condition in 
a tertiary teaching hospital.
METHODS
In this cross-sectional analysis, we studied patients 
submitted to cardiac valve surgery who underwent 
predischarge echocardiographic examination between 
January 2012 and July 2014, in the Hospital de 
Clínicas de Porto Alegre. The institutional review 
board approved the study and waived written informed 
consent.
Data were extracted from medical records and 
the Department of Cardiac Surgery administrative 
registry using a standardized form. We collected 
preoperative data about previous comorbidities, 
medication use, blood tests, imaging exams, and 
surgical indication; intraoperative data about surgery 
time and surgical technique; and postoperative 
data about thoracic drainage, medication use, atrial 
fibrillation, stroke, severe bleeding, reinterventions, 
readmissions, and mortality.
Of the 353 identified patients, 335 were included 
in this study (16 patients died and two patients did not 
undergo a predischarge echocardiography). Patients 
were categorized into two groups: moderate-to-severe 
PE and absent or small PE (figure 1). Moderate-to-severe 
PE was defined as ≥ 10 mm of thickness6, or signs 
of cardiac tamponade on echocardiography. Patients 
who did not match these criteria were classified as 
absent of small PE.
Statistical Analysis
Data were presented as mean and standard 
deviation or median and interquartile range (IQR) 
(continuous data) or as count and proportion 
(categorical and ordinal data). Continuous variables 
were compared using the independent-samples 
t test and categorical variables were compared 
using the chi-square test. After univariate screening, 
multivariable linear regression was used to adjust 
for selected clinically and statistically significant 
pre-and intraoperative covariates (age, sex, history 
of stroke, preoperative international normalized ratio 
(INR) levels, and surgery time).
All statistical analyses were performed with PASW 
18.0 (SPSS Inc, Chicago). All tests were two-sided 
and p-values of < 0.05 were considered statistically 
significant.
RESULTS
Patients
The majority of echocardiographic examinations 
were conducted up to 6 days of after surgery (median: 
6.0 days; IQR: 5.0-7.0). From January 2012 to July 
2014, moderate-to-severe PE occurred in 27 (8%) 
of 335 patients submitted to cardiac valve surgery 
(mean age: 62; standard deviation 12 years; 70% 
male). Five of those presented with echocardiographic 
signs of increased intrapericardial pressure or clinical 
cardiac tamponade. Patients with moderate-to-severe 
PE had more history of stroke and asthma than 
absent or small PE patients, but were similar to 
those with respect to other preoperative clinical and 
echocardiographic characteristics (table 1). The group 
with moderate-to-severe PE had lower hemoglobin 
and hematocrit levels, higher INR, and a higher 
prevalence of INR greater than 2 compared to the 
absent or small PE group (table 2). The association 
between moderate-to-severe PE and preoperative 
INR levels remained statistically significant after 
adjustments.
Figure 1: (A) Small pericardial effusion (< 10 mm) and (B) Large pericardial effusion (≥ 10 mm) on the postoperative 
echocardiographic examination. RV: right ventricule, LV: left ventricule, Ao: Aorta, LA: left atrium.
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Table 1: Preoperative characteristics.
Moderate-to-Severe PE
(n=27)
Absent or Small PE 
(n=308) p value
Age, years 62±12 61±14 0.108
Male 19 (70) 156 (51) 0.049
BMI, kg/m2 27.3±5.1 27.6±5.1 0.629
Body surface area, m2 1.85±0.23 1.79±0.22 0.800
Skin color, white 27 (100) 290 (94) 0.434
Diabetes 7 (26) 67 (22) 0.616
Dyslipidemia 6 (22) 48 (16) 0.368
Hypertension 16 (59) 214 (70) 0.272
Heart Failure 13 (48) 173 (56) 0.421
Ischemic Heart Disease 6 (22) 81 (26) 0.643
Stroke 6 (22) 23 (8) 0.009
Immunosuppression 1 (4) 4 (1) 0.323
Chronic Renal Disease 2 (7) 24 (8) 0.943
Asthma 3 (11) 8 (3) 0.017
COPD 3 (11) 13 (4) 0.107
Atrial fibrillation 0.586
Paroxysmal 2 (7) 11 (4)
Persistent/Permanent 4 (15) 41 (13)
Previous Cardiac Surgery 3 (11) 29 (9) 0.774
Preoperative medications
Antiplatelet agents* 9 (33) 110 (36) 0.804
Oral anticoagulants** 5 (19) 29 (9) 0.133
Nitrate 0 (0) 23 (8) 0.141
Antihypertensive drugs*** 22 (82) 248 (81) 0.904
Digitalis 4 (15) 39 (13) 0.748
Antiarrhythmic agents 1 (4) 17 (6) 0.688
Echocardiographic findings
Aortic diameter, cm 3.3±0.6 3.4±0.6 0.870
Left atrium diameter, cm 4.9±0.8 4.6±0.8 0.648
LV diastolic diameter, cm 5.7±1.2 5.4±1.0 0.696
LV systolic diameter, cm 3.7±1.0 3.6±1.0 0.606
Septum thickness, cm 1.1±0.2 1.1±0.3 0.113
LV posterior wall, cm 1.0±0.2 1.0±0.2 0.217
Ejection fraction, % 62±14 61±12 0.824
RV diameter, cm 2.4±0.4 2.3±0.5 0.660
BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; LV: Left Ventricle; PE: Pericardial Effusion; RV: Right Ventricle. 
*Antiplatelet agents: Aspirin or clopidogrel. **Anticoagulants: Warfarin or new oral anticoagulants. ***Antihypertensive drugs: beta-blockers, 
angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics. Data are presented as mean ± SD 
or n (percentage).
Table 2: Preoperative laboratory data.
Moderate-to-Severe PE
(n=27)
Absent or Small PE
(n=308) p value
INR 1.27±0.75 1.05±0.19 < 0.001
INR > 2 3 (11) 7 (2) 0.002
Platelets, x 103 mg/dL 212±60 216±71 0.673
Hematocrit, % 37.2±7.5 38.1±5.3 0.038
Hemoglobin, mg/dL 12.4±2.7 12.8±2.0 0.027
Creatinine, mg/dL 1.3±1.5 1.2±1.0 0.091
INR: International Normalized Ratio; PE: Pericardial Effusion. Data are presented as mean ± SD and n (percentage).
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Surgery
The most performed surgery was aortic valve 
replacement (70%) and the most common indication 
for the procedure was aortic valve stenosis (55%). 
Ninety-three (28%) patients were submitted to multiple 
procedures (for example, aortic valve replacement 
and coronary artery bypass graft surgery) during 
the surgery. Patients with moderate-to-severe PE 
had longer surgeries, as well as longer periods of 
ischemia and cardiopulmonary bypass (table 3). 
Surgical status (elective or urgent/emergent surgery) 
did not differ between groups, nor did the proportion 
of patients submitted to multiple procedures.
Postoperative Parameters
Postoperative data are presented in Table 4. Patients 
with moderate-to-severe PE had longer periods with 
thoracic drain than patients with absent or small PE, 
with a mean difference of 5.3 hours (33.6 hours vs. 
28.3 hours; p = 0.001), though the total drained volume 
Table 3: Surgical parameters.
Moderate-to-Severe PE
(n=27)
Absent or Small PE 
(n=308) p value
Surgical status 0.363
Elective 24 (89) 288 (93)
Urgent/Emergent 3 (11) 20 (7)
Multiple indications 6 (22) 97 (32) 0.317
Multiple procedures 6 (22) 87 (28) 0.503
Total surgery time, min 183±62 159±50 0.041
Ischemia time, min 71±30 58±22 < 0.001
CPB time, min 88±35 74±26 < 0.001
CPB: Cardiopulmonary Bypass. Data are presented as mean ± SD or n (percentage).
Table 4: Postoperative parameters.
Moderate-to-Severe PE
(n=27)
Absent or Small PE
(n=308) p value
Days with drain 1.4±0.9 1.18±0.5 0.001
Atrial fibrillation 15 (56) 97 (32) 0.011
New onset atrial fibrillation 10 (37) 62 (20) 0.038
Medications
Anticoagulants* 19 (70) 179 (58) 0.214
Antiplatelet agents** 7 (26) 168 (55) 0.004
NSAIDs 6 (22) 34 (11) 0.086
Colchicine 8 (30) 11 (4) < 0.001
Corticosteroids 5 (19) 9 (3) < 0.001
Echocardiographic findings
Aortic diameter, cm 3.4±0.5 3.4±0.6 0.143
Left atrium diameter, cm 4.9±0.7 4,5±0.8 0.551
LV diastolic diameter, cm 5.1±0.6 5.1±0.9 0.155
LV systolic diameter, cm 3.6±0.8 3.5±0.9 0.290
Septum thickness, cm 1.1±0.2 1.1±0.3 0.113
LV posterior wall, cm 1.1±0.2 1.1±0.2 0.307
Ejection fraction,% 58±12 58±13 0.842
RV diameter, cm 2.3±0.3 2.3±0.5 0.300
Reoperation for bleeding 4 (15) 14 (5) 0.023
Reoperation for other causes 3 (11) 7 (2) 0.010
Days of hospitalization 24±17 15±13 0.007
Deaths 4 (15) 9 (3) 0.002
*Anticoagulants = Warfarin or Heparin or Enoxaparin. **Antiplatelet agents: Aspirin or Clopidogrel. NAIDs: Nonsteroidal anti-inflammatory 
drugs; LV: Left ventricle; RV: Right Ventricle. Data are presented as mean ± SD or n (percentage).
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did not differ. Moderate-to-severe PE patients had a 
lower postoperative prescription of antiplatelet agents, 
i.e. aspirin or clopidogrel (p = 0.004), and a similar use 
of anticoagulants compared to patients with absent 
or small PE. Additionally, Moderate-to-severe PE 
patients had a higher use of colchicine (p < 0.001) 
and corticosteroids (p < 0.001) due to suspected 
postpericardiotomy syndrome. The time to start 
the postoperative medications, including oral 
anticoagulant therapy, and postoperative blood test 
results were similar between the groups. There was 
also no difference in postoperative echocardiographic 
measures. The moderate-to-severe PE group 
had more reintervention for bleeding (15% vs. 
5%; p=0.023) and for other causes (11% vs. 2%; 
p=0.01), and three patients developed clinical cardiac 
tamponade. This group also had more episodes 
of postoperative atrial fibrillation (56% vs. 32%, 
p=0,011). The hospitalization was longer in patients 
with moderate-to-severe PE compared to those with 
absent or small PE (24±17 days vs. 15 ± 13 days; 
p = 0.007). The rate of postoperative deaths was 
significantly higher in patients from the group with 
moderate-to-severe PE (15% vs. 3%; p = 0.002).
DISCUSSION
In this study, the incidence of moderate-to-severe 
PE following cardiac valve surgery was 8%. We found 
that patients who develop moderate-to-severe PE 
had a higher prevalence of previous stroke, higher 
levels of preoperative INR, longer surgery times, and 
higher prevalence of new and recurrent postoperative 
atrial fibrillation than patients with absent or small 
PE. Moreover, the group with moderate-to-severe PE 
underwent more reinterventions (for bleeding and for 
other causes) and had a greater number of deaths.
The high variability of the reported PE incidence 
after cardiac surgery is related to the different 
definitions for this condition3,7,8. Our study used only 
echocardiographic parameters to define PE, while 
others used clinical presentation and echocardiographic 
data7; however, our incidence of PE is in the lower 
range of published incidence rates. This may be 
attributed to the fact that echocardiograms were 
systematically performed in all patients, regardless 
of symptoms.
Preoperative Considerations
We identified that history of stroke was a risk 
factor for the development of moderate-to-severe PE. 
This association could be attributed to a higher use 
of antiplatelet agents and anticoagulants aiming at 
secondary prevention. Although not statistically significant, 
the prevalence of anticoagulated patients was almost 
twice as high in the group with moderate-to-severe 
PE, which is likely to be clinically relevant. Besides 
that, higher levels of preoperative INR was the most 
important factor associated with moderate-to-severe 
PE. Some studies have found association between the 
previous use of immunosuppressive therapy and the 
development of postoperative PE4,9, although we only 
had two patients taking these drugs. The protective 
association between history of previous cardiac 
surgery and PE reported in other studies4,10,11 was 
not present in our analysis.
Intraoperative Considerations
Patients with moderate-to-severe PE were more 
likely to have longer surgeries, with longer periods of 
ischemia and cardiopulmonary bypass. This finding 
has already demonstrated to be an important risk 
factor for PE3,12, which may be related to changes 
in coagulation parameters during these periods. We 
did not find differences in the types of cardiac valve 
replacement and the type of prosthesis (mechanic or 
biologic). Some authors have shown that aortic root 
and aortic aneurysm surgery are independent risk 
factors for the development of significant postoperative 
PE due to prolonged cardiopulmonary bypass and 
extensive dissection of the heart and the aorta4,13,14. 
In this study, we analyzed the combination of aortic 
root with cardiac valve replacement, but we did not 
find a higher risk to develop moderate-to-severe PE 
in this subgroup.
Postoperative Considerations
Patients with moderate-to-severe PE presented 
higher rate of postoperative atrial fibrillation than 
absent or small PE patients, similarly to the results 
described by Ikäheimo et al.8 Arrhythmia can be a 
marker of higher risk of adverse outcomes in these 
patients15,16 which may have mediated a higher incidence 
of clinical endpoints regardless the presence of PE.
Aspirin reduces the risk of death and ischemic 
complications12 after coronary artery bypass 
grafting, but it is associated with a higher risk of 
postoperative PE3,17. In our analysis, patients with 
moderate-to-severe PE used less aspirin and had 
a similar use of anticoagulants compared to absent 
or small PE patients. This finding reinforces the 
safety of early postoperative aspirin administration 
regarding PE risk.
The efficacy of anticoagulation after cardiac valve 
surgery depends on a delicate balance between the 
risk of thromboembolic events and risk of bleeding, 
and the appropriate time to start these drugs is not 
clear18,19. Although PE is one of the main concerns 
regarding proper anticoagulation initiation, our data 
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are not enough to suggest a specific recommendation 
in this aspect.
The association between the time of chest tube 
removal and PE is a controversial topic. Most of our 
patients had their chest drainage removed on the 
second postoperative day. Some authors showed 
that there is no difference between early (< 24 hours) 
and late (≥ 24 hours) chest tube removal20,21. Chest 
tube withdrawal delay would increase the risk of 
infection and would cause more discomfort to 
patients22,23, but its early removal could predispose 
to the development of PE24. In our study, we did not 
find significant difference between the groups with 
respect to time of chest tube removal.
The development of moderate-to-severe PE was 
related to higher risk of reinterventions and death. 
The causes of deaths were related to cardiogenic 
shock and septic shock. Only patients from the 
group of moderate-to-severe PE presented cardiac 
tamponade. Although, Kuvin et al.3 reported a high 
rate of cardiac tamponade after postoperative 
moderate-to-severe PE (74%), we found a rate of 
11% among patients with moderate-to-severe PE. 
This discrepancy may be due to differences in the 
definition of cardiac tamponade.
Study Limitations
Some limitations of this analysis should be noted. 
Although most of our results are consistent with 
what was reported in the literature, our sample of 
moderate-to-severe PE patients was small and our 
study was based on a retrospective analysis of medical 
records limited to one study center. We analyzed only 
cardiac valve surgeries, since all these patients should 
have undergone an echocardiographic examination 
before hospital discharge as a routine of our service. 
Additionally, we lack information about the high risk 
group, since we excluded patients who died before 
performing the hospital discharge routine.
CONCLUSION
In our study, the incidence of moderate-to-severe 
PE in patients submitted to cardiac valve surgery is 
not low, but still in the lower range of previous reports. 
This condition may be associated with preoperative 
coagulation state, and also with prolonged surgery and 
postoperative higher morbidity and mortality. Identifying 
risk factors associated with moderate-to-severe PE 
may help to better prevent or reduce the occurrence 
of this condition.
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